Коррекция Экспериментальной Ишемической Нейропатии Зрительного Нерва Агонистом Имидазолиновых Рецепторов Типов I И II

Пересыпкина, Анна Александровна; Покровский, М. В.; Должиков, А. А.; Levkova, E. A.; Pobeda, Anna

doi:10.30906/0869-2092-2018-81-4-12-17

Cited by 2 publications

(3 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ophthalmoscopy in rats was performed according to the method previously published by us [21,28]. To dilate the pupil, 2.5% Irifrin eye drops (Promed Exports, India) were used.…”

Section: Ophthalmoscopymentioning

confidence: 99%

See 1 more Smart Citation

Retinoprotective Effect of 2-Ethyl-3-hydroxy-6-methylpyridine Nicotinate

Peresypkina

Pazhinsky

Даниленко

et al. 2020

Biology

View full text Add to dashboard Cite

An important task of pharmacology is to find effective agents to improve retinal microcirculation and resistance to ischemia. The purpose of the study is to pharmacologically evaluate the retinoprotective effect of 2-ethyl-3-hydroxy-6-methylpyridine nicotinate in a rat model of retinal ischemia–reperfusion. A retinal ischemia–reperfusion model was used, in which an increase in intraocular pressure (IOP) to 110 mmHg was carried out within 30 min. The retinoprotective effect of 2-ethyl-3-hydroxy-6-methylpyridine nicotinate at a dose of 3.8 mg/kg, in comparison with nicotinic acid at a dose of 2 mg/kg and emoxipine at a dose of 2 mg/kg, was estimated by the changes in the eye fundus during ophthalmoscopy, the retinal microcirculation level with laser Doppler flowmetry (LDF), and electroretinography (ERG) after 72 h of reperfusion. The use of 2-ethyl-3-hydroxy-6-methylpyridine nicotinate prevented the development of ischemic injuries in the fundus and led to an increase in the retinal microcirculation level to 747 (median) (lower and upper quartiles: 693;760) perfusion units (p = 0.0002) in comparison with the group that underwent no treatment. In the group with the studied substance, the b-wave amplitude increased significantly (p = 0.0022), and the b/a coefficient increased reliably (p = 0.0002) in comparison with the group with no treatment. Thus, 2-ethyl-3-hydroxy-6-methylpyridine nicotinate has established itself as a potential retinoprotector.

show abstract

“…Ophthalmoscopy in rats was performed according to the method previously published by us [21,28]. To dilate the pupil, 2.5% Irifrin eye drops (Promed Exports, India) were used.…”

Section: Ophthalmoscopymentioning

confidence: 99%

“…Treatment of ischemic retinal conditions is done using angioprotectors, antioxidants, fibrinolytics, and anticoagulants [21]. Due to the instability effects when carrying out drug therapy, it is necessary to seek out more effective methods to increase resistance to retinal ischemia [26][27][28].…”

Section: Introductionmentioning

confidence: 99%

Retinoprotective Effect of 2-Ethyl-3-hydroxy-6-methylpyridine Nicotinate

Peresypkina

Pazhinsky

Даниленко

et al. 2020

Biology

View full text Add to dashboard Cite

show abstract

“…Ophthalmoscopy was performed as described elsewhere (Peresypkina et al 2018b), using the OI-78M (Volk Optical Inc, Mentor, OH, USA) lense.…”

Section: Ophthalmoscopymentioning

confidence: 99%

Study to elucidate the pharmacological activity of retinalamin in a rat model of ischemic retinopathy

Pobeda¹,

Kalatanova²,

Abasheva³

et al. 2021

RRP

View full text Add to dashboard Cite

Introduction: Over the past few years, the incidence of retinal ischemic disorders has been increasing, due to a rising prevalence of such socially burdensome diseases as diabetes and hypertension, which ultimately lead to ocular vascular pathology. The identification of new treatment options that would prevent retinal neuron death is a crucial task of modern pharmacology. Materials and methods: The research was carried out on male Wistar rats. Retinopathy was modeled by inducing a 30-min ischemic episode, with a 72-hour period of reperfusion and subsequent administration of Retinalamin and Emoxypine for 10 days. The effectiveness of the drugs was evaluated by electroretinographic, ophthalmoscopic and morphological assessments. Results and discussion: On Day 14 of the experiment, a dose-dependent preservation of the electroretinogram b-wave/a-wave amplitude ratio was observed in the animals treated with Retinalamin depending on a dose (1.39±0.06, 1.46±0.03 and 1.49±0.04 in low (0.214 mg/kg), medium (0.428 mg/kg) and high (0.857 mg/kg) Retinalamin dose groups, respectively). The ophthalmoscopic picture of the fundus oculi also improved following the treatment with Retinalamin (1.42, 1.69 and 1.90 times lower ophthalmoscopic scores compared to placebo-treated animals in low, medium and high dose groups, respectively). The morphologic “coefficient of change” applied to ganglion cell layer was 2.2, 1.7 and 1.6 points in low, medium and high dose Retinalamin groups, respectively. These results are significantly different from both intact and placebo group (p<0.05). Based on the aforementioned experimental findings, we conclude that Retinalamin has a retinoprotective effect and is superior to the drug of comparison (Emoxypine). Conclusion: The greatest neuroprotective effects were shown in the groups receiving Retinalamin. In these groups, the ERG b-wave/a-wave amplitude ratio was preserved, the ophthalmoscopic picture was less pathologic and retinal morphology features were close to those of the intact retina.

show abstract

Коррекция Экспериментальной Ишемической Нейропатии Зрительного Нерва Агонистом Имидазолиновых Рецепторов Типов I И II

Cited by 2 publications

References 5 publications

Retinoprotective Effect of 2-Ethyl-3-hydroxy-6-methylpyridine Nicotinate

Retinoprotective Effect of 2-Ethyl-3-hydroxy-6-methylpyridine Nicotinate

Study to elucidate the pharmacological activity of retinalamin in a rat model of ischemic retinopathy

Contact Info

Product

Resources

About